24 results
Thumbnail

D2.76 - Disease Control, Activity and Quality of Life in Chronic Spontaneous Urticaria A Cross-Sectional Study from Kazakhstan

Thumbnail

D2.77 - Lanadelumab in C1-Esterase Inhibitor Non-Responding patient: A Case Report

Thumbnail

D2.83 - Management of Non IgE Cow's Milk Allergy: Current Practices and Challenges

Thumbnail

D2.75 - Prevalence of Attention Deficit Hyperactivity Disorder and Related Factors in Children Aged 6-14 Years Diagnosed with Allergic Rhinitis

Thumbnail

D2.78 - Comparative analysis of IgE reactivity to fish extracts versus beta-parvalbumin molecules in allergic patients

Thumbnail

D2.79 - Cannabis Sensitization as an Underrecognized Airborne Trigger in Uncontrolled Asthma: A Case Report

Thumbnail

D2.80 - Development of Standardized Case Report Forms to Support Biomarker-Based Differential Diagnosis of Bradykinin-Mediated Angioedema

Thumbnail

D2.82 - Analytical Performance Evaluation of Cor a 8, Cor a 9, and Cor a 14 Hazelnut Components on IMMULITE 2000 XPi*

Thumbnail

D2.84 - Avoiding Mislabeling of Drug Allergy in Patients with Recurrent Cutaneous Symptoms

Thumbnail

D2.85 - Analytical Performance Evaluation of Bet v 4 and Cor a 1 on IMMULITE 2000 XPi*

Thumbnail

D2.86 - Nasal Nitric Oxide in Routine Practice: Results of a One-Year Clinical Experience in Pediatric Allergology

Thumbnail

D2.88 - Drug Provocation Testing for Suspected Beta-Lactam Allergy in Children: Experience from a Secondary Hospital in the Community of Madrid

Thumbnail

D2.89 - Basophil Testing Beyond Positivity: Are There More Endotypes in Chronic Spontaneous Urticaria?

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria